Spotlight On... Dialysis provider Fresenius creates regenerative medicine biz; FDA approves novel prostate cancer imaging agent; BioVentrix to start pivotal trial for ischemic cardiomyopathy device; and more...

Fresenius Medical Care is planning for beyond dialysis. It's created a new regenerative medicine subsidiary, known as Unicyte, with partner University of Turin. It has a long-standing relationship with the university that dates back to 2003. Unicyte will do research into the application of regenerative medicine to kidney and liver diseases, diabetes and cancer. The transfer of liver stem cells into other cell types as well as the creation of functional pancreatic islets are some of the research projects it will undertake. More

> Westminster, CO-based startup CardioNXT has raised $1.5 million from Solas BioVentures and existing investors to back its cardiac arrhythmia products that aim to reduce the cost of cardiac ablation procedures. More

> The FDA has approved Blue Earth Diagnostics' Axumin (Fluciclovine F 18) for recurrent prostate cancer PET imaging after a priority review. More

> BioVentrix has been given the go-ahead from the FDA to start a pivotal trial of its Revivent TC TransCatheter Ventricular Enhancement System, which is used in a hybrid closed-chest transcatheter procedure to treat patients suffering from ischemic cardiomyopathy by reshaping and restoring the left ventricle. More